Novel Anti Human Ctgf Antibody

Abstract: [Problem] To provide: an anti human CTGF antibody having a superior binding activity and/or a superior neutralization activity compared with those of conventional anti human CTGF antibodies; and a means for preventing or treating various diseases in which human CTGF is involved in the formation of clinical conditions thereof including renal diseases such as chronic kidney disease and diabetic nephropathy using the above mentioned anti human CTGF antibody. [Solution] An anti human CTGF antibody containing a heavy chain variable region comprising the amino acid sequence represented by SEQ ID NO: 10 and a light chain variable region comprising the amino acid sequence represented by SEQ ID NO: 4.

Patent Information

Application #

Filing Date

19 June 2014

Publication Number

38/2015

Publication Type

INA

Invention Field

BIOTECHNOLOGY

Status

Email

patent@depenning.com

Parent Application

Applicants

ASTELLAS PHARMA INC.

5 1 Nihonbashi Honcho 2 chome Chuo ku Tokyo 1038411

Inventors

1. IWASAKI Shoji

c/o Astellas Pharma Inc. 3 11 Nihonbashi Honcho 2 chome Chuo ku Tokyo 1038411

2. MORIYA Ryuichi

c/o Astellas Pharma Inc. 3 11 Nihonbashi Honcho 2 chome Chuo ku Tokyo 1038411

3. YOSHINO Masayasu

c/o Astellas Pharma Inc. 3 11 Nihonbashi Honcho 2 chome Chuo ku Tokyo 1038411

4. TAKAKURA Koji

c/o Astellas Pharma Inc. 3 11 Nihonbashi Honcho 2 chome Chuo ku Tokyo 1038411

Specification

Claims
[Claim 1] An anti-human CTGF antibody, comprising:
a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 10; and
a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 4.
[Claim 2] The anti-human CTGF antibody according to claim 1, wherein a heavy-
chain constant region of the antibody is a human Igyl constant region.
[Claim3] The anti-human CTGF antibody according to claim 1, wherein a light-
chain constant region of the antibody is a human IgK constant region.
[Claim 4] The anti-human CTGF antibody according to claim 1, wherein a heavy-
chain constant region of the antibody is a human Igyl constant region, and a light-chain constant region of the antibody is a human IgK constant region.
[Claim 5] The anti-human CTGF antibody according to claim 1, comprising:
a heavy chain consisting of the amino acid sequence shown by SEQ ID NO: 12;
and
a light chain consisting of the amino acid sequence shown by SEQ ID NO: 8.
[Claim 6] A polynucleotide comprising a sequence that encodes the heavy-chain
variable region of the antibody according to claim 1.
[Claim 7] A polynucleotide comprising a sequence that encodes the light-chain
variable region of the antibody according to claim 1.
[Claim 8] An expression vector comprising the polynucleotide according to claim 6
and/or claim 7.
[Claim 9] A host cell transformed with the expression vector according to claim 8.
[Claim 10] The host cell according to claim 9, which is selected from the group
consisting of the following (a) and (b):
(a) a host cell transformed with an expression vector comprising a polynucleotide comprising a sequence that encodes the heavy-chain variable region of the antibody

according to claim 1 and a polynucleotide comprising a sequence that encodes the light-chain variable region of the antibody; and
(b) a host cell transformed with an expression vector comprising a polynucleotide comprising a sequence that encodes the heavy-chain variable region of the antibody according to claim 1, and an expression vector comprising a polynucleotide comprising a sequence that encodes the light-chain variable region of the antibody.
[Claim 11] A method for producing the anti-human CTGF antibody according to
claim 1, the method comprising expressing the anti-human CTGF antibody by culturing the host cell according to claim 9 or 10.